Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab - AbbVie/AstraZeneca

Next Previous
Drug Profile

Adalimumab - AbbVie/AstraZeneca

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Abbott Laboratories; AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Hidradenitis suppurativa; Ulcerative colitis; Uveitis; Pyoderma gangrenosum; Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Registered Pyoderma gangrenosum
  • Discontinued Interstitial cystitis

Most Recent Events

  • 08 Apr 2025 AbbVie initiates a phase III trial for Ulcerative colitis (In children, In adolescents) in Japan, Poland, Slovakia, Spain, UK, US (SC) (NCT02632175)
  • 06 Dec 2024 Discontinued - Phase-III for Ulcerative colitis in Ukraine (SC) (AbbVie pipeline, December 2024)
  • 09 Aug 2022 Arecor Therapeutics has patent protection for adalimumab in the European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top